Algert Global LLC Merus N.V. Transaction History

Algert Global LLC

$3.01 Billion
Q2 2024

A detailed history of Algert Global LLC transactions in Merus N.V. stock. As of the latest transaction made, Algert Global LLC holds 133,323 shares of MRUS stock, worth $6.36 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

133,323

Previous 97,774 36.36%

Holding current value

$6.36 Million

Previous $4.4 Million 79.17%

% of portfolio

0.26%

Previous 0.17%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$39.81 - $60.2 $1.42 Million - $2.14 Million	35,549 Added 36.36%	133,323 $7.89 Million
Q1 2024 May 14, 2024	BUY	$28.03 - $51.82 $808,413 - $1.49 Million	28,841 Added 41.84%	97,774 $4.4 Million
Q4 2023 Feb 14, 2024	SELL	$20.06 - $28.66 $31,072 - $44,394	-1,549 Reduced 2.2%	68,933 $1.9 Million
Q3 2023 Nov 13, 2023	SELL	$20.13 - $27.29 $588,198 - $797,413	-29,220 Reduced 29.31%	70,482 $1.66 Million
Q2 2023 Aug 14, 2023	SELL	$18.33 - $27.18 $222,819 - $330,400	-12,156 Reduced 10.87%	99,702 $2.63 Million
Q1 2023 May 12, 2023	BUY	$14.25 - $20.5 $302,969 - $435,850	21,261 Added 23.47%	111,858 $2.06 Million
Q4 2022 Feb 13, 2023	BUY	$12.8 - $23.66 $498,944 - $922,266	38,980 Added 75.52%	90,597 $1.4 Million
Q3 2022 Nov 15, 2022	BUY	$18.64 - $28.93 $85,632 - $132,904	4,594 Added 9.77%	51,617 $1.03 Million
Q2 2022 Aug 15, 2022	BUY	$13.98 - $29.25 $59,135 - $123,727	4,230 Added 9.88%	47,023 $1.07 Million
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $657,292 - $861,616	27,875 Added 186.85%	42,793 $1.13 Million
Q4 2021 Feb 14, 2022	SELL	$20.0 - $32.29 $19,000 - $30,675	-950 Reduced 5.99%	14,918 $474,000
Q3 2021 Nov 15, 2021	BUY	$16.48 - $27.23 $261,504 - $432,085	15,868 New	15,868 $349,000

Others Institutions Holding MRUS

# of Institutions

188

Shares Held

59M

Call Options Held

345K

Put Options Held

222K

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.19B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Merus N.V. Transaction History